Actively Recruiting
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
Led by Fudan University · Updated on 2024-02-23
160
Participants Needed
1
Research Sites
200 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Describe the efficacy and safety of Orelabrutinib in the treatment of HP-positive gastric MALT lymphoma
CONDITIONS
Official Title
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histologically confirmed gastric mucosa-associated lymphoid tissue (MALT) lymphoma
- Current infection with Helicobacter pylori confirmed by rapid urease test, histological staining, bacterial culture, urea breath test, or HpSA detection
- ECOG performance status of 0 to 2
- Lugano staging I to II1
- Signed informed consent form
- Presence of evaluable lesions
You will not qualify if you...
- Negative for Helicobacter pylori infection
- History of other tumors except cured cervical cancer or basal cell carcinoma of the skin
- Active HIV or syphilis infections
- Pregnant or breastfeeding women
- Severe active infections
- Conditions affecting ability to take oral medication such as dysphagia, nausea, vomiting, chronic diarrhea, or intestinal obstruction
- Other health conditions preventing completion of the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
Y
Yizhen Liu, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here